CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER) (KOV-HIPEC-02R)
Randomized Phase III Trial of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Resistant Recurrent Ovarian Cancer: KOV-02R - Resistant Cancer of Ovary (RECOVER)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Myong Cheol Lim, MD, Ph.D
- Phone Number: +820319201760
- Email: mclim@ncc.re.kr
Study Contact Backup
- Name: Ji Hyun Kim, MD
- Phone Number: +8201026835747
- Email: jihyunkim@ncc.re.kr
Study Locations
-
-
-
Seoul, South Korea
- Korea University Anam Hospital
-
Seoul, South Korea
- Ewha Womans University Mokdong Hospital
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, South Korea, 10408
- Myong Cheol Lim
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients ≥18 years old,
- Patients with Eastern Cooperative Oncology Group (ECOG) Performance status 0-2,
- Patients diagnosed with histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer,
- Resistant to platinum-based chemotherapy (Platinum-refractory or resistant disease)
- Resectable intraperitoneal disease based on previous clinical history and recent image finding,
- A life expectancy > 3 months as clinically judged,
- Women who are medically unable to conceive or who are of childbearing potential, agree to follow contraceptive guidelines during treatment,
- Patient can also consent to the provision of clinical information for secondary use such as future biomedical research. However, in the future, subjects can participate in the main trial even if they do not intend to participate in sharing clinical information and,
- Adequate organ function for cytoreductive surgery and HIPEC
Exclusion criteria:
- Non-epithelial ovarian carcinoma,
- Borderline ovarian tumor,
- Patients who are not appropriate for surgical and HIPEC procedures based on previous surgery or clinical findings, including severe intestinal adhesions, obstruction, or abdominal fistula,
- Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML,
- Patients which extra-abdominal disease is a major disease or is expected to cause of death,
- Patients with active central nervous system metastasis and carcinoma meningitis or patients who have been previously treated for brain metastases must be in a stable state in radiology,
- Patients with antibacterial, antifungal, or antiviral infections requiring systemic treatment (administration of parenteral antibiotics),
- Active tuberculosis that is not controlled within 1 month of treatment,
- Patient diagnosed with a psychiatric disorder or substance abuse disorder that would interfere with your ability to cooperate with the trial,
- Patients who have not undergone hysterectomy and have a positive urine pregnancy test result within 14 days prior to clinical trial assignment, even if the urine pregnancy test result is negative at screening,
- Pregnant or lactating women,
- Patients with any contraindications to the use of doxorubicin or mitomycin (i.e., hypersensitivity to doxorubicin or mitomycin),
- Patients with a history of allogeneic tissue/solid organ transplantation or bone marrow transplantation or a history of double umbilical cord transplantation or,
- History or current evidence of any condition, therapy, or laboratory abnormality that may confound the results of the study, interfere with the patient's participation, in the opinion of the treating investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: No HIPEC
Physician-choice chemotherapy from enrollment until disease progression.
|
|
|
Experimental: Cytoreductive surgery and HIPEC
Cytoreductive surgery + Hyperthermic Intraperitoneal Chemotherapy (HIPEC) followed by physician-choice chemotherapy until disease progression.
|
HIPEC perfusion, doxorubicin 35mg/m2 & mitomycin 15 mg/m2, 41.5'C, 90 min.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free survival (PFS)
Time Frame: From randomization to time of first progression or death from any cause, whichever came first, assessed up to 5 years
|
From randomization to time of first progression or death from any cause, whichever came first, assessed up to 5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival (OS)
Time Frame: From randomization to the date of death from any cause, assessed up to 5 years
|
From randomization to the date of death from any cause, assessed up to 5 years
|
|
|
cancer-specific survival
Time Frame: From randomization to the date of death due to ovarian cancer, assessed up to 5 years
|
From randomization to the date of death due to ovarian cancer, assessed up to 5 years
|
|
|
Treatment-related adverse events
Time Frame: From randomization up to the end of treatment plus 6 weeks
|
assessed by CTCAE ver.5.0
|
From randomization up to the end of treatment plus 6 weeks
|
|
Health-related quality of life (QLQ C30)
Time Frame: Over the 5 year surveillance period
|
assessed by EEuropean Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Score 30 (QLQ-C30)
|
Over the 5 year surveillance period
|
|
Health-related quality of life (QLQ OV28)
Time Frame: Over the 5 year surveillance period
|
assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Ovarian Cancer Module (QLQ-OV28)
|
Over the 5 year surveillance period
|
|
Health-related quality of life (EQ-5D-5L)
Time Frame: Over the 5 year surveillance period
|
assessed by the 5-level EQ-5D version (EQ-5D-5L)
|
Over the 5 year surveillance period
|
|
Cost-effectiveness analysis
Time Frame: At time of completion of 5-year surveillance period
|
assessed by Quality-Adjusted Live Years (QALYs)
|
At time of completion of 5-year surveillance period
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Genital Diseases, Female
- Endocrine Gland Neoplasms
- Neoplasms, Glandular and Epithelial
- Ovarian Diseases
- Adnexal Diseases
- Genital Neoplasms, Female
- Gonadal Disorders
- Carcinoma
- Carcinoma, Ovarian Epithelial
- Ovarian Neoplasms
- Therapeutics
- Drug Therapy
- Hyperthermia, Induced
- Combined Modality Therapy
- Chemotherapy, Adjuvant
- Hyperthermic Intraperitoneal Chemotherapy
Other Study ID Numbers
Other Study ID Numbers
- NCC2021-0334
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.